Stay updated with breaking news from Operational Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data...
Oil Exploration Co. Releases Exciting Operational Updates
Obe-cel, a potentially transformational treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia , on track for a Biologics License Application submission to the US Food & Drug...
Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistanceRoche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of mul...
01.08.2023 - Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially ...